Delineating the Cytogenomic and Epigenomic Landscapes of Glioma Stem Cell Lines

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Baronchelli, Simona ^a,b   Bentivegna, Angela ^a   Redaelli, Serena ^a   Riva, Gabriele ^a   Butta, Valentina ^a   Paoletta, Laura ^a   Isimbaldi, Giuseppe ^c   Miozzo, Monica ^d,e   Tabano, Silvia ^d,e   Daga, Antonio ^f   Marubbi, Daniela ^f,g   Cattaneo, Monica ^b   Biunno, Ida ^h   Dalprà, Leda ^a,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h Milan Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAMTA1 GENE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CHROMOSOME 10; CHROMOSOME 13; CHROMOSOME 7; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; EGFR GENE; EPIGENETICS; FETUS; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PTEN GENE; RB1 GENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; GENOMICS; GLIOMA; HUMANS; HYDROGEN-ION CONCENTRATION; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASTIC STEM CELLS;

EID: 84874562227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057462     Document Type: Article

References (85)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
2. Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, et al. (2012) Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 123: 841-852.
3. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, et al. (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48: 1176-1184.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
5. Wen PY, Kesari S, (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
6. Bonavia R, Inda MM, Cavenee WK, Furnari FB, (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71: 4055-4060.
7. Nowell PC, (1976) The clonal evolution of tumor cell populations. Science 194: 23-28.
8. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
9. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, et al. (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206.
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
11. Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, et al. (2010) Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci 101: 416-424.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
13. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
14. Lobo NA, Shimono Y, Qian D, Clarke MF, (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
15. Visvader JE, Lindeman GJ, (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 717-728.
16. Magee JA, Piskounova E, Morrison SJ, (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296.
17. Rahman M, Deleyrolle L, Vedam-Mai V, Azari H, Abd-El-Barr M, et al. (2011) The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 68: 531-545; discussion 545.
18. Shackleton M, Quintana E, Fearon ER, Morrison SJ, (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.
19. Greaves M, (2010) Cancer stem cells: back to Darwin? Semin Cancer Biol 20: 65-70.
20. Network CGAR, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
21. Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, et al. (2010) Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 29: 73-93.
22. Ichimura K, Ohgaki H, Kleihues P, Collins VP, (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70: 137-160.
23. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710.
24. Huse JT, Holland EC, (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331.
25. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, et al. (2009) Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28: 1807-1811.
26. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, et al. (2009) Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 7: 383-392.
27. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
28. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, et al. (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27: 2091-2096.
29. Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, et al. (2008) Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 8: 304.
30. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, et al. (2009) Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 15: 6541-6550.
31. Li A, Walling J, Kotliarov Y, (2008) Center A, Steed ME, et al (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6: 21-30.
32. Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, et al. (2009) Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 284: 7138-7148.
33. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580.
34. Sun Y, Pollard S, Conti L, Toselli M, Biella G, et al. (2008) Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci 38: 245-258.
35. Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi MG, et al. (2011) Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS One 6: e24237.
36. Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, et al. (2007) Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenetics. Am J Med Genet A 143A: 1679-1686.
37. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, et al. (2009) Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 16: 564-571.
38. Beissbarth T, Speed TP, (2004) GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20: 1464-1465.
39. Aronica E, Boer K, Becker A, Redeker S, Spliet WG, et al. (2008) Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience 151: 272-292.
40. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
41. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M, (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128.
42. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 104: 5527-5532.
43. Cadieux B, Ching TT, VandenBerg SR, Costello JF, (2006) Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66: 8469-8476.
44. Bird A, (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21.
45. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
46. Carén H, Pollard SM, Beck S (2012) The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma. Mol Aspects Med. doi:10.1016/j.mam.2012.06.007.
47. Liu WM, Laux H, Henry JY, Bolton TB, Dalgleish AG, et al. (2010) A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep 37: 1801-1814.
48. de Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, et al. (2009) Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 48: 55-68.
49. Lo KC, Rossi MR, LaDuca J, Hicks DG, Turpaz Y, et al. (2007) Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer 46: 875-894.
50. Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, et al. (2006) Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 66: 11502-11513.
51. Nord H, Hartmann C, Andersson R, Menzel U, Pfeifer S, et al. (2009) Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol 11: 803-818.
52. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
53. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, et al. (2006) Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25: 1261-1271.
54. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, et al. (1995) Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett 97: 241-247.
55. Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, et al. (2008) 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27: 2097-2108.
56. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, et al. (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18: 4144-4152.
57. Bauer A, Savelyeva L, Claas A, Praml C, Berthold F, et al. (2001) Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosomes Cancer 31: 228-239.
58. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, et al. (2010) Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70: 2030-2040.
59. Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, et al. (2011) CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. EMBO J 30: 4309-4322.
60. Cerami E, Demir E, Schultz N, Taylor BS, Sander C, (2010) Automated network analysis identifies core pathways in glioblastoma. PLoS One 5: e8918.
61. Pack SD, Alper OM, Stromberg K, Augustus M, Ozdemirli M, et al. (2004) Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 64: 789-794.
62. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, et al. (2012) Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition. Neoplasia 14: 420-428.
63. Sherry MM, Reeves A, Wu JK, Cochran BH, (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27: 2383-2392.
64. Wang H, Lathia JD, Wu Q, Wang J, Li Z, et al. (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404.
65. Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, et al. (2009) Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett 284: 71-79.
66. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
67. Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, et al. (2008) Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev 22: 2028-2033.
68. Regenbrecht CR, Lehrach H, Adjaye J, (2008) Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev 4: 319-328.
69. Esteller M, (2005) Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 45: 629-656.
70. Dahl JA, Duggal S, Coulston N, Millar D, Melki J, et al. (2008) Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol 52: 1033-1042.
71. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
72. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, et al. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27: 2897-2909.
73. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, et al. (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5: e114.
74. Sadikovic B, Al-Romaih K, Squire JA, Zielenska M, (2008) Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 9: 394-408.
75. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, et al. (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4: 255-264.
76. He Q, Li G, Su Y, Shen J, Liu Q, et al. (2010) Single minded 2-s (SIM2-s) gene is expressed in human GBM cells and involved in GBM invasion. Cancer Biol Ther 9: 430-436.
77. Okada T, Suehiro Y, Ueno K, Mitomori S, Kaneko S, et al. (2010) TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer 49: 452-462.
78. Li Y, Zhang Y, He B, Wang Y, Yuan Z, et al. (2007) Cloning and expression of a novel human gene, Isl-2, encoded a LIM-homeodomain protein. Mol Biol Rep 34: 19-26.
79. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326.
80. Ringrose L, Paro R, (2004) Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38: 413-443.
81. Martinez R, Esteller M, (2010) The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39: 40-46.
82. Schuebel K, Chen W, Baylin SB, (2006) CIMPle origin for promoter hypermethylation in colorectal cancer? Nat Genet 38: 738-740.
83. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, et al. (2010) CpG island hypermethylation in human astrocytomas. Cancer Res 70: 2718-2727.
84. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, et al. (2008) Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci U S A 105: 4844-4849.
85. Martín-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, et al. (2009) New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113: 2488-2497.